StemCell Therapy

The 56 rating InvestorsObserver gives to Capricor Therapeutics Inc (CAPR) stock puts it near the middle of the Biotechnology industry. In addition to scoring higher than 60 percent of stocks in the Biotechnology industry, CAPRs 56 overall rating means the stock scores better than 56 percent of all stocks.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Capricor Therapeutics Inc (CAPR) stock is trading at $1.12 as of 11:11 AM on Wednesday, Mar 18, a decline of -$0.05, or -4.27% from the previous closing price of $1.17. Volume today is above average. So far 1,088,965 shares have traded compared to average volume of 154,691 shares. The stock has traded between $1.05 and $1.45 so far today.

To see InvestorsObserver's Sentiment Score for Capricor Therapeutics Inc click here.

Read more from the original source:
How Does Capricor Therapeutics Inc (CAPR) Stock Compare to Other Stocks in Biotechnology? - InvestorsObserver

The 50 rating InvestorsObserver gives to DBV TECHNOLOGIE/S ADR (DBVT) stock puts it near the middle of the Biotechnology industry. In addition to scoring higher than 47 percent of stocks in the Biotechnology industry, DBVTs 50 overall rating means the stock scores better than 50 percent of all stocks.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 50 means the stock is more attractive than 50 percent of stocks.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

DBV TECHNOLOGIE/S ADR (DBVT) stock is trading at $2.81 as of 9:51 AM on Wednesday, Mar 18, an increase of $0.48, or 20.46% from the previous closing price of $2.33. The stock has traded between $2.76 and $3.10 so far today. Volume today is below average. So far 171,742 shares have traded compared to average volume of 741,694 shares.

To see the top 5 stocks in Biotechnology click here.

Read this article:
Industry Breakdown: Where Does DBV TECHNOLOGIE/S ADR (DBVT) Stock Fall in the Biotechnology Field? - InvestorsObserver

NEW YORK, March 18, 2020 /PRNewswire/ --

Trends, opportunities, and forecast in microsphere market to 2025 by end use industry (Composites, Medical Technology, Life Sciences and Biotechnology, Paints and Coatings, Cosmetics and Personal Care, and Others), product type (Hollow Microsphere and Solid Microsphere), material (Glass Microspheres, Polymer Microspheres, Ceramic Microspheres, Fly Ash Microspheres, Metallic Microspheres, and Others), and region (North America, Europe, Asia Pacific, and the Rest of the World)

Read the full report: https://www.reportlinker.com/p05876009/?utm_source=PRN

According to a new market report, the future of the global microsphere market looks promising with opportunities in the composites, medical technology, life science & biotechnology, and painting & coating industries. The global microsphere market is forecast to reach $4.7 billion by 2025 with a CAGR of 7.1% from 2020 to 2025. The major drivers for this market are the growing demand for higher efficiency and lightweight materials and superior structural and enhanced properties of microsphere over conventional fillers.Emerging trends, which have a direct impact on the dynamics of the industry, include continuous research and development to improve drug delivery system and development of biodegradable microspheres.

The study includes trends and forecast for the global microsphere market by product type, end use industry, material, and region as follows:

By End Use Industry [$M and Kilotons Shipment Analysis for 2014 2025]: Composites Medical Technology Life Sciences and Biotechnology Paints and Coatings Cosmetics and Personal Care Others

By Material Type ($M and Kilotons Shipment Analysis for 2014 2025): Glass Microsphere Polymer Microsphere Ceramic Microsphere Fly Ash Microsphere Metallic Microsphere Others

By Product [$M and Kilotons Shipment Analysis for 2014 2025]: Hollow Microsphere Solid Microsphere

By Region [$M and Kilotons Shipment Analysis for 2014 2025]: North America United States Canada Mexico Europe Germany France Spain Italy Asia Pacific China India Japan Korea The Rest of the WorldSome of the microsphere companies profiled in this report include 3M, Cospheric, Trelleborg, and AkzoNobel Expancel.

The analyst forecasts that glass microsphere will remain the largest material segment over the forecast period, as it provides lower viscosity, high melting point, and higher chemical resistance than other types of microsphere.

Composites is projected to remain the largest end use industry, and it is also expected to witness the highest growth during the forecast period due to increasing demand for lightweight materials in various end use industries.

North America will remain the largest region, and it is also expected to witness the highest growth over the forecast period due to increasing demand for composites in automobiles and growth in medical technology.

Some of the features of "Global Microsphere Market: Trends, Forecast and Competitive Analysis" Include: Market Size Estimates: Microsphere market size estimation in terms of value ($M) and volume (kilotons) shipment. Trends and Forecast Analysis: Market trends (2014-2019) and forecast (2020-2025) by various segments. Segmentation Analysis: Microsphere market size by various segments, such as product type, material, and end use industry, in terms of value and volume shipment. Regional Analysis: Microsphere market breakdown by North America, Europe, Asia Pacific, and the Rest of the World. Growth Opportunities: Analysis on growth opportunities in different end use industries, product types, material types, and regions for the microsphere market. Strategic Analysis: This includes M&A, new product development, and competitive landscape for the microsphere market. Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers the following 11 key questions:________________________________________

Q.1 What are some of the most promising potential, high-growth opportunities for the global microsphere market by end use industry (Composites, Medical Technology, Life Sciences & Biotechnology, Paints & Coatings, Cosmetics & Personal Care, and Others), product type (Hollow Microsphere and Solid Microsphere), material (Glass Microspheres, Polymer Microspheres, Ceramic Microspheres, Fly Ash Microspheres, Metallic Microspheres, and Others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?Q.2 Which segments will grow at a faster pace and why?Q.3 Which regions will grow at a faster pace and why?Q.4 What are the key factors affecting market dynamics? What are the drivers and challenges of the market?Q.5 What are the business risks and threats to the market?Q.6 What are emerging trends in this market and the reasons behind them?Q.7 What are some changing demands of customers in the market?Q.8 What are the new developments in the market? Which companies are leading these developments?Q.9 Who are the major players in this market? What strategic initiatives are being implemented by key players for business growth?

Read the full report: https://www.reportlinker.com/p05876009/?utm_source=PRN

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

View original content:http://www.prnewswire.com/news-releases/the-global-microsphere-market-is-forecast-to-reach-4-7-billion-by-2025-with-a-cagr-of-7-1-from-2020-to-2025--301026041.html

SOURCE Reportlinker

See original here:
The global microsphere market is forecast to reach $4.7 billion by 2025 with a CAGR of 7.1% from 2020 to 2025 - Yahoo Finance

The Asia-Pacific bioinformatics market is projected to be the fastest growing regional market in the forecast period.

The introduction and adoption of cloud computing and nanopore technology are expected to offer numerous opportunities in the global bioinformatics market. The nanopore technology has been projected for getting used in the study of crop science, deoxyribonucleic acid (DNA), ribonucleic acid (RNA), proteins and small molecules with a range of applications in personalized medicine, and scientific research.

Download sample copy of this report@www.psmarketresearch.com/market-ort-sample

Bioinformatics is a discipline that deals with the retrieval, storage, processing, management and analysis of organic information through computational techniques. Bioinformatics plays an important role in drug innovation and improvement.

The involvement of bioinformatics in storing, retrieving, analyzing and forming biological information helps in efficiently managing enormous database associated with drug innovation and development.

On the basis of sector, the global bioinformatics market is fundamentally divided into forensic biotechnology, medical biotechnology, academics, environmental biotechnology, animal biotechnology and agriculture biotechnology. The medical biotechnology segment can be further classified into molecular medicine, drug development, gene therapy, clinical diagnostics and reproductive biotechnology.

Based on applications, the market is categorized into molecular phylo genetics, chemo informatics & drug design genomics, proteomics, transcriptomics and metabo lomics.

Pre-AccessInquiry at@www.psmarketresearch.com/send-enics-market

Bioinformatics technologies are used in various pharmaceutical and biotechnology sectors. They are mainly used in the medical sector, which is driven by the increasing use of bioinformatics for the drug development and discovery process.

Falling prices of DNA sequencing and increasing government initiatives to boost bioinformatics based life sciences research activities are the two major growth drivers of the global bioinformatics market. Some of the other drivers contributing to growth the of global bioinformatics market includes, increasing demand for bioinformatics as a consulting solution by pharmaceutical manufacturers and medical devices, in an effort to accelerate and improve manufacturing processes, with the increasing need for bioinformatics in data incorporation and warehousing.

Some of the key competitors within the global bioinformatics market include Tripos, LP, Affymetrix, Inc, Agilent Technologies, Illumina, Inc., Helicos Biosciences Corporation, IBM Life Sciences, Thermo Fisher Scientific Inc, Rosetta Inpharmatics LLC, Celera and others.

This email address is being protected from spambots. You need JavaScript enabled to view it.

Go here to read the rest:
Current research: Bioinformatics Market trends, share, growth drivers and forecast report by 2030 - WhaTech Technology and Markets News

DUBLIN--(BUSINESS WIRE)--The "Worldwide Wound Care Market Summary" report has been added to ResearchAndMarkets.com's offering.

Wound care is very much a challenge for both patients and healthcare providers.

The wound care market is a technologically enriched environment dedicated to advancing wound care therapies.

This report identifies a market opportunity for major sectors of this important market. A particular focus is given to biotechnology used in wound care, including advanced biodressings and negative pressure wound systems. The report focuses on wound care advancements, providing a table of newly approved wound care products for 2019.

The aging of the population and continued advances in biotechnology drive the wound care industry. It is the goal of new and existing product manufacturers to offer products designed to improve healing rates and prevent wound formation.

Market data in the report includes:

World Market

Total Market by Segment

Market Segments by Application

Market by Application

The report also contains current market size for the total wound care products market for the following countries and regions:

Advancements in biotechnology, biomaterials, and tissue engineering are expected to drive growth in the market during the report's forecast period. Growth is also being driven by the introduction of portable, single-use products in negative pressure wound therapy.

Worldwide Wound Care Market Summary provides an outline of the competitive market, including the following data points:

Industry participants have attempted to diversify their offerings by acquiring smaller companies with new and innovative technology. This move has created more competition among large wound care companies.

Key Topics Covered:

Chapter 1: Executive Summary

Chapter 2: Total Worldwide Wound Care Market Size, Forecast, and Competitive Analysis

Chapter 3: Wound Care Advancements

Chapter 4: Top Five Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/g31rxc

Follow this link:
Outlook into the Worldwide Wound Care Market to 2024 - Top 5 Competitors in the Global Industry - ResearchAndMarkets.com - Business Wire

The report by HNY Research covers complete analysis of the Red Biotechnology report on a regional and global level. The report comprises several drivers and restraints of the Red Biotechnology. Likewise, it covers the complete segmentation analysis such as type, application, and region. This report provides information on key manufactures, industry chain analysis, competitive insights, and macroeconomic analysis. Global Red Biotechnology report provides the latest forecast market data, industry trends, and technological innovations. The in-depth view of Red Biotechnology industry on the basis of market size, market growth, opportunities, and development plans offered by the report analysis. The forecast information, SWOT analysis, and feasibility study are the energetic aspects studied in this report.

Request a sample of this report @ https://www.orbisresearch.com/contacts/request-sample/4372598

Manufacturer Detail

By Market Players:

By Application

By TypeAntibody, Nucleic Acid, Protein, Other

By F. Hoffmann-La RocheAmgen, Gilead Sciences, CSL, Pfizer

The study covers the production, sales, and revenue of various top players in the global Red Biotechnology market, therefore enabling customers to achieve thorough information of the competition and henceforth plan accordingly to challenge them and grasp the maximum market share. This report also focusses on significant statistics and information for the consumers to attain in-depth data of the Red Biotechnology and further Red Biotechnology growth. The up-to-date, complete product knowledge, end users, industry growth will drive the profitability and revenue. Red Biotechnology report by HNY Research studies the current state of the market to analyze the future opportunities and risks. Red Biotechnology report provides a 360-degree global market state. Primarily, the report delivers Red Biotechnology introduction, overview, market objectives, market definition, scope, and market size valuation.

Browse the complete report @ https://www.orbisresearch.com/reports/index/2020-2025-global-and-regional-red-biotechnology-industry-production-sales-and-consumption-status-and-prospects-professional-market-research-report

Red Biotechnology report helps the end-users to understand the industry plans, growth factors, development strategies and policies implemented by leading Red Biotechnology players. This report analyses various facts and figures to grow the global Red Biotechnology revenue. A detailed explanation of Red Biotechnology potential consumers, market values, and the future scope are offered in this report. The key players of Red Biotechnology industry, their product portfolio, market share, industry profiles is studied in this report. The major market players are studied on the basis of gross margin, production volume, price structure, and market value. The competitive scenario among Red Biotechnology players will help the industry contenders in planning their policies. The report statistics covered in this report will be a beneficial guide to form the business growth.

Make an enquiry of this report @ https://www.orbisresearch.com/contacts/enquiry-before-buying/4372598

On global level Red Biotechnology industry report by HNY Research segments the data on the basis of product type, applications, and regions. Regional Red Biotechnology segmentation analyses the market across regions such as North America, Europe, China, Japan, India, Middle East & Africa, South Africa, Southeast Asia, and South America. It also focusses on market dynamics, Red Biotechnology growth drivers, developing market segments and the market growth curve is offered based on past, present and future market statistics.

About Us:

Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Us:Hector CostelloSenior Manager Client Engagements4144N Central Expressway,Suite 600, Dallas,Texas 75204, U.S.A.Phone No.: USA: +1 (972)-362-8199 | IND: +91 895 659 5155Email ID: [emailprotected]

Continue reading here:
2020-2025 Global and Regional Red Biotechnology Industry Production, Sales and Consumption Status and Prospects Professional Market Research Report -...

Vir Biotechnology, Inc. (San Francisco, CA, USA) has entered into a collaboration with Biogen Inc. (Cambridge, MA, USA) for the development and clinical manufacturing of human monoclonal antibodies (mAbs) for the potential treatment of COVID-19, the disease caused by the SARS-CoV-2 virus.

Vir Biotechnology is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The company has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Vir has a robust method for capitalizing on unusually successful immune responses naturally occurring in people who are protected from, or have recovered from, infectious diseases. The platform is used to identify rare antibodies from survivors that have the potential to treat and prevent rapidly evolving and/or previously untreatable pathogens via direct pathogen neutralization and immune system stimulation. Vir engineers the fully human antibodies that it discovers to enhance their therapeutic potential. The company has identified a number of mAbs that bind to SARS-CoV-2, which were isolated from individuals who had survived a SARS (Severe Acute Respiratory Syndrome) infection. The company is conducting research to determine if its antibodies, or additional antibodies that it may be able to identify, can be effective as treatment and/or prophylaxis against SARS-CoV-2.

Due to the urgency of the situation, Vir and Biogen have begun work while a Clinical Development and Manufacturing Agreement is being negotiated. Subject to the completion of a definitive agreement, Biogen would continue cell line development, process development, and clinical manufacturing activities in order to advance the development of Virs proprietary antibodies.

These exceptional circumstances presented by the threat of COVID-19 require that we work with great urgency in the interest of the public good, said George Scangos, Ph.D., CEO, Vir. Biogen is one of the global leaders in cell line and process development for advanced biologics; tapping into their capabilities will provide us with a U.S. base for supply and manufacture of antibody therapies.

Similarly, Vir has also entered into a research collaboration agreement with the National Institutes of Health (NIH) and the National Institute of Allergy and Infectious Diseases (NIAID), Vaccine Research Center (VRC) to advance characterization and development of mAbs against coronaviruses. The joint project will augment ongoing efforts by both parties to identify antibodies that can be used to prevent or treat infection with existing and emerging viruses and help inform the development of vaccines. Vir and NIAID will work together to identify and optimize combinations of antibodies against coronaviruses, including SARS-CoV-2, SARS and MERS, as well as antibodies that may be effective across additional types of coronaviruses. The two parties will exchange antibodies and other materials for testing in combination and individually and, by mutual agreement, will perform in vivo animal studies to analyze immune responses.

This collaboration expands Virs efforts to characterize and develop antibody therapies against coronaviruses by allowing us to access the VRCs significant and broad research experience with coronaviruses, which is complementary to ours, said Herbert Skip Virgin, M.D., Ph.D., Chief Scientific Officer, Vir. This is one of multiple approaches we are taking to rapidly identify and test potential prophylactics and therapeutics for COVID-19 and we expect it to allow us to accelerate finding solutions to this urgent public health need.

Related Links:Vir Biotechnology, Inc. Biogen Inc.

Go here to read the rest:
Vir Biotechnology Partners with NIH and Biogen for Developing Coronavirus Antibodies - HospiMedica

NEW YORK Stocks that moved heavily or traded substantially on Thursday:

United Airlines Holdings Inc., down $12.26 to $37.08.

The U.S. is restricting travel from most of Europe for 30 days over the virus outbreak.

Boeing Co., down $34.24 to $154.84.

The airplane maker is reportedly freezing hiring and could draw down the remainder of a $13.8 billion loan.

Apache Corp., down 49 cents to $7.76.

The oil and gas company is cutting spending, reducing its rig count and drastically slashing its dividend.

Expedia Group Inc., down $11.63 to $65.04.

The economic impact from the virus outbreak is expected to inflict severe financial pain on travel-reliant companies.

United Parcel Service Inc., down $1.82 to $86.17.

The package delivery service said board member Carol Tome will take over from its retiring CEO.

Vir Biotechnology Inc., up $3.83 to $37.60.

The biotechnology company will work with Biogen to develop a potential treatment for COVID-19.

Live Nation Entertainment Inc., down $5.81 to $36. 20.

The concert promoter faces a dismal outlook as the virus outbreak cancels large public events.

Carnival Corp., down $6.78 to $14.97.

The companys Princess Cruises will suspend global operations through May 10 because of the virus outbreak.

See more here:
Live Nation, Carnival fall; Vir Biotechnology, rises - The Republic

COVID-19 continues to spread worldwide. The latest situation report from the World Health Organization (WHO) shows that there are now more than 125,000 confirmed cases of the disease and more than 4,600 deaths. Several biotech companies are racing to find a vaccine or a treatment for the rapidly spreading disease.

One of these companies is Vir Biotechnology (NASDAQ:VIR), which focuses on developing treatments for infectious diseases. Recently, Vir announced it was partnering up with Biogen (NASDAQ:BIIB) to develop and manufacture antibodies that could treat COVID-19. Given the gravity of the situation, the two companies decided to start working on this project while negotiating the terms of the deal.

Image Source: Getty Images.

On Jan. 22, Vir announced it was screening its library of antibodies to identify one that could be effective against COVID-19. The company had previous experience dealing with other coronaviruses, including Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS). On Feb. 12, Vir announced it identified two antibodies with the potential to be effective against SARS-CoV-2, the virus that causes COVID-19.

The company partnered with other companies in its quest to beat the potentially deadly disease. Vir entered into an agreement with WuXi Biologics, a China-based biologics technology platform that helps companies develop and manufacture drugs.According to the terms of the deal, WuXi Biologics "will conduct cell-line development, process and formulation development, and initial manufacturing for clinical development." WuXi Biologics will hold the right to market this treatment in China if it is approved, and Vir will market it in the rest of the world.

Continue reading here:
Biogen and Vir Biotechnology to Collaborate to Find a Treatment for the Coronavirus - The Motley Fool

This press release was orginally distributed by SBWire

Pune, India -- (SBWIRE) -- 03/16/2020 -- Data Bridge Market Research recently added "Agricultural biotechnology market by manufacturers, regions, type and application, forecast to 2027" in his database. This research report focus on complete assessment of market and contains future trend, growth factors, attentive opinions, facts, historical data, statistically supported and industry validated market data. Environmental concerns & regulatory guidelines regarding release of effluents through different industries. Agricultural biotechnology market comprehensive coverage of underlying economic and technological factors under key trend analysis.

Agricultural biotechnology market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to account to USD 74.55 billion by 2027 growing at a CAGR of 9.94% in the above-mentioned forecast period. Escalated penetration of biotechnology, tissue culture, and molecular breeding and unique plant breeding is defining the success parameters of agricultural biotechnology market.

This agricultural biotechnology research report covers every aspects of the global market and presents it in easy to read format. The report also categories the industry into key geographical regions, sub regions, types and Applications. The global market study covers everything that a stakeholder needs to know about the Industry, complete with the sales, value, volume, market size and growth opportunities. The Market study covers everything that a stakeholder needs to know about the industry, complete with the sales, value, Volume, Market size and growth Opportunities.

Download Sample PDF Copy of Report https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-agricultural-biotechnology-market

The major players covered in the agricultural biotechnology market report are KWS SAAT SE & Co. KGaA, ChemChina, Corteva., Limagrain, MITSUI & CO., LTD., AgPlenus ltd., Biomica, Evogene Ltd., Canonic ltd., Bayer AG, Valent BioSciences LLC, Nufarm Limited, Marrone Bio Innovations., Performance Plants Inc., ADAMA Ltd. among other domestic and global players. Market share data is available for global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Major Topics Covered in this Report:

Chapter 1 Study Coverage

Chapter 2 Executive Summary

Chapter 3 Market Size by Manufacturers

Chapter 4 Production by Regions

Chapter 5 Consumption by Regions

Chapter 6 Market Size by Type

Chapter 7 Market Size by Application

Chapter 8 Manufacturers Profiles

Chapter 9 Production Forecasts

Chapter 10 Consumption Forecast

For More Insights Get Detailed TOC https://www.databridgemarketresearch.com/toc/?dbmr=global-agricultural-biotechnology-market

Global Agricultural Biotechnology Market Scope and Market Size

Agricultural biotechnology market is segmented on the basis of type, application, organism type, technology, and product. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

On the basis of type, agricultural biotechnology market is segmented into molecular diagnostics, molecular markers, tissue culture, vaccines, genetic engineering, and others.On the basis of application, the agricultural biotechnology market is bifurcated into transgenic crops, flower culturing, nutritional supplements, biofuels, antibiotic development, vaccine development and others.On the basis of organism type, the agricultural biotechnology market is divided into plants, animals, microbes, and others.On the basis of technology, the agricultural biotechnology market is fragmented into genome editing tools, ribonucleic acid interference [RNAi], biochips, deoxy ribonucleic acid [DNA] sequencing, and synthetic biology.Based on the product, the agricultural biotechnology market is segregated into crop protection products, transgenic seeds, and synthetic biology-enables products. Crop protection products are further sub-categorized into biostimulants, and biopesticides. Transgenic seeds are further sub-segmented into soybean, fruits & vegetables, maize, cotton, and others.Inquiry For Customize Report With Discount At https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-agricultural-biotechnology-market

About Data Bridge Market ResearchData Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. Get Customization and Discount on Report by emailing sopan.gedam@databridgemarketresearch.com . We are content with our glorious 99.9 % client satisfying rate.

Contact:

Data Bridge Market ResearchUS: +1 888 387 2818UK: +44 208 089 1725Hong Kong: +852 8192 7475Email: Corporatesales@databridgemarketresearch.com

For more information on this press release visit: http://www.sbwire.com/press-releases/global-agricultural-biotechnology-market-industry-size-growth-opportunities-outlook-and-forecast-2020-to-2027canonic-ltd-bayer-ag-valent-biosciences-llc-nufarm-limited-marrone-bio-innovations-performance-plants-inc-adama-ltd-1280300.htm

More here:
Global Agricultural Biotechnology Market Industry Size, Growth, Opportunities, Outlook and Forecast 2020 to 2027:Canonic Ltd., Bayer AG, Valent...

In this report, the global Agriculture Biotechnology market is valued at USD XX million in 2019 and is projected to reach USD XX million by the end of 2025, growing at a CAGR of XX% during the period 2019 to 2025.

For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2019 to 2025.

The Agriculture Biotechnology market report firstly introduced the basics: definitions, classifications, applications and market overview; product specifications; manufacturing processes; cost structures, raw materials and so on. Then it analyzed the worlds main region market conditions, including the product price, profit, capacity, production, supply, demand and market growth rate and forecast etc. In the end, the Agriculture Biotechnology market report introduced new project SWOT analysis, investment feasibility analysis, and investment return analysis.

Request Sample Report @ https://www.researchmoz.com/enquiry.php?type=S&repid=2057155&source=atm

The major players profiled in this Agriculture Biotechnology market report include:

The key players covered in this studyADAMA Agricultural SolutionsVilmorinBayerBiocentury TransgeneCertisDow AgroSciencesEurofinsEvogeneGlobal Bio-chem TechnologySyngentaKWS SaatMarina BiotechMonsanto

Market segment by Type, the product can be split intoBiochipsDeoxy ribonucleic acid (DNS) sequencingGenome editing toolsRibonucleic acid interference (RNAI)Synthetic biology

Market segment by Application, split intoTransgenic crops marketSynthetic biology-enabled products market

Market segment by Regions/Countries, this report coversUnited StatesEuropeChinaJapanSoutheast AsiaIndiaCentral & South America

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2057155&licType=S&source=atm

The study objectives of Agriculture Biotechnology Market Report are:

To analyze and research the Agriculture Biotechnology market status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.

To present the Agriculture Biotechnology manufacturers, presenting the sales, revenue, market share, and recent development for key players.

To split the breakdown data by regions, type, companies and applications

To analyze the global and key regions Agriculture Biotechnology market potential and advantage, opportunity and challenge, restraints and risks.

To identify significant trends, drivers, influence factors in global and regions

To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the keyword market.

Make An EnquiryAbout This Report @ https://www.researchmoz.com/enquiry.php?type=E&repid=2057155&source=atm

More here:
Agriculture Biotechnology Projected to Witness a Single-Digit CAGR During 2019-2025 - Daily Science

SOUTH SAN FRANCISCO, Calif., March 16, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation(Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that a consortium of medical schools led by the Icahn School of Medicine at Mount Sinaiis utilizing Fluidigm microfluidics technology to create an epigenetic test for early detection of the novel coronavirus that causes COVID-19. The spread of this disease has been declared a global pandemic by the World Health Organization.

Part of the Epigenetic CHaracterization and Observation (ECHO) program of the U.S.Defense Departments Defense Advanced Research Projects Agency (DARPA), the consortium is developing a testusing real-time PCR for host detection assays targeting epigenome and viral RNA for early-stage monitoring of potentially infected individuals.

Incorporating the Fluidigm Biomark HD system and the companys microfluidics technology, a single integrated fluidic circuit (IFC) can screen 192 samples across 24 different parallel processed assays to allow early detection of the virus infection. Labs will be able to generate more than 6,000 individual test results per day with just one hour of hands-on time, representing a scale and parallel processing of assays not possible using microwell plates.

The consortium led by the Icahn School of Medicine plans to submit the test for Emergency Use Authorization, in accordance with U.S. Food and Drug Administration (FDA) guidelines, for a high-throughput screening assay for COVID-19 based on robust real-time PCR. It will employ the high-throughput sample processing capacity of the Biomark HD coupled with parallel multi-assay interrogation of microfluidics.

Speed, scale and early detection are critical in addressing the spread of the COVID-19 pandemic, and the ability to rapidly screen a large number of samples will enhance capabilities in identification and management of infected individuals, including those who are asymptomatic, said Chris Linthwaite, President and CEO of Fluidigm. We believe the application of Fluidigm microfluidics technologies to epigenetic testing for COVID-19 has significant potential to increase the speed and capacity of these critical screening efforts.

Fluidigm is committed to supporting the efforts of the consortium and others in addressing the rapidly evolving global COVID-19 pandemic. We believe that partnering with other developers and labs seeking Emergency Use Authorization for tests utilizing our unique IFC technology has the potential to add significant testing capacity. Quick and reliable detection is crucial to combat this rapidly advancing pandemic.

Microfluidics technology generates more data and uses a fraction of expensive testing reagents per precious sample as compared with more traditional, microwell plate-based PCR technology. Fluidigm Biomark HD and microfluidics technology, in particular, enable the automated assembly of PCRs at the nanoscale level in a massively parallel manner.

We appreciate the unique expertise Fluidigm brings to this multi-institution, DARPA-supported effort to develop an early test for COVID-19, said Professor Stuart C. Sealfon, MD, principal investigator of the DARPA ECHO program and Director of the Center for Advanced Research on Diagnostic Assays and Chairman Emeritus of the Department of Neurology at the Icahn Sinai School of Medicine.

About FluidigmFluidigm(Nasdaq:FLDM) is an industry-leading biotechnology toolsprovider with a vision to improve life through comprehensive health insight. We focus on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF and microfluidics technologies, we develop, manufacture, and market multi-omic solutions to drive meaningful insights in health and disease, identify biomarkers to inform decisions, and accelerate the development of more effective therapies. Our customers are leading academic, government, pharmaceutical, biotechnology, and plant and animal research laboratories worldwide. Together with them, we strive to increase the quality of life for all. For more information, visitfluidigm.com.

Fluidigm, theFluidigmlogo, Biomark, and CyTOF are trademarks and/or registered trademarks ofFluidigm Corporationinthe United Statesand/or other countries. Fluidigm products are provided for Research Use Only. Not for use in diagnostic procedures.

Forward-Looking Statements for FluidigmThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding the implementation of Fluidigm microfluidics technology and products by third parties and the anticipated benefits of, and applications and demand for, such products. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including but not limited to risks relating to challenges inherent in developing, manufacturing, launching, marketing, and selling new products; risks relating to company research and development and distribution plans and capabilities; interruptions or delays in the supply of components or materials for, or manufacturing of, Fluidigm products; potential product performance and quality issues; intellectual property risks; and competition. Information on these and additional risks and uncertainties and other information affectingFluidigmbusiness and operating results is contained in Fluidigms Annual Report on Form 10-K for the year endedDecember 31, 2019, and in its other filings with theSecurities and Exchange Commission. These forward-looking statements speak only as of the date hereof.Fluidigmdisclaims any obligation to update these forward-looking statements except as may be required by law.

Contacts:

Media:Mark SpearmanSenior Director, Corporate Communications650 243 6621mark.spearman@fluidigm.com

Investors:Agnes LeeVice President, Investor Relations650 416 7423agnes.lee@fluidigm.com

Go here to see the original:
Consortium of Medical Schools Led by Mount Sinai Fast-Tracking COVID-19 Detection Test Utilizing Fluidigm Microfluidics Technology - GlobeNewswire

The recent performance of Puma Biotechnology (NASDAQ:PBYI) stock in the market spoke loud and clear to investors as PBYI saw more than 2.07M shares in trading volumes in the last trading session, way higher than the average trading volume of 2.07M shares by far recorded in the movement of Puma Biotechnology (PBYI). At the time the stock opened at the value of $7.90, making it a high for the given period, the value of the stock jumped by 3.11%. After the increase, PBYI touched a low price of $6.62, calling it a day with a closing price of $7.39, which means that the price of PBYI went 7.62 below the opening price on the mentioned day.

Given the most recent momentum in the market in the price movement of PBYI stock, some strong opinions on the matter of investing in the companys stock started to take shape, which is how analysts are predicting an estimated price of $12.63 for PBYI within consensus. The estimated price would demand a set of gains in total of 22.75%, which goes higher than the most recent closing price, indicating that the stock is in for bullish trends. Other indicators are hinting that the stock could reach an outstanding figure in the market share, which is currently set at 34.75M in the public float and 375.67M US dollars in market capitalization.

When it comes to the technical analysis of PBYI stock, there are more than several important indicators on the companys success in the market, one of those being the Relative Strength Indicator (RSI), which can show, just as Stochastic measures, what is going on with the value of the stock beneath the data. This value may also indicate that the stock will go sideways rather than up or down, also indicating that the price could stay where it is for quite some time. When it comes to Stochastic reading, PBYI stock are showing 10.95% in results, indicating that the stock is neither overbought or oversold at the moment, providing it with a neutral within Stochastic reading as well. Additionally, PBYI with the present state of 200 MA appear to be indicating bearish trends within the movement of the stock in the market. While other metrics within the technical analysis are due to provide an outline into the value of PBYI, the general sentiment in the market is inclined toward negative trends.

With the previous 100-day trading volume average of 602215 shares, IMAX Corporation (IMAX) recorded a trading volume of 1.95 million shares, as the stock started the trading session at the value of $10.85, in the end touching the price of $11.10 after jumping by 2.30%.

IMAX stock seem to be going ahead the lowest price in the last 52 weeks with the latest change of 3.06%.Then price of IMAX also went backward in oppose to its average movements recorded in the previous 20 days. The price volatility of IMAX stock during the period of the last months recorded 6.88%, whilst it changed for the week, now showing 12.63% of volatility in the last seven days. The trading distance for this period is set at -29.31% and is presently away from its moving average by -36.70% in the last 50 days. During the period of the last 5 days, IMAX stock lost around -26.15% of its value, now recording a dip by -45.14% reaching an average $20.18 in the period of the last 200 days.During the period of the last 12 months, IMAX Corporation (IMAX) dropped by -45.67%.

According to the Barcharts scale, the companys consensus rating was unchanged to 4.86 from 4.86, showing an overall improvement during the course of a single month. Based on the latest results, analysts are suggesting that the target price for IMAX stock should be $11.10 per share in the course of the next 12 months. To achieve the target price as suggested by analysts, IMAX should have a spike by 0% in oppose to its present value in the market. Additionally, the current price showcases a discount of 58.89% when compared to the high consensus price target predicted by analysts.

IMAX shares recorded a trading volume of 2.55 million shares, compared to the volume of 804.68K shares before the last close, presented as its trading average. With the approaching 12.63% during the last seven days, the volatility of IMAX stock remained at 6.88%. During the last trading session, the lost value that IMAX stock recorded was set at the price of $11.10, while the lowest value in the last 52 weeks was set at $10.77. The recovery of the stock in the market has notably added 3.06% of gains since its low value, also recording -37.54% in the period of the last 1 month.

Continued here:
What Will Eventually Wobble Puma Biotechnology (PBYI), IMAX Corporation (IMAX) - US Post News

Moderna Inc (MRNA) is near the top in its industry group according to InvestorsObserver. MRNA gets an overall rating of 64. That means it scores higher than 64 percent of stocks. Moderna Inc gets a 74 rank in the Biotechnology industry. Biotechnology is number 11 out of 148 industries.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 64 means the stock is more attractive than 64 percent of stocks.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Moderna Inc (MRNA) stock is higher by 9.39% while the S&P 500 has fallen -10.28% as of 9:49 AM on Monday, Mar 16. MRNA has risen $2.00 from the previous closing price of $21.30 on volume of 1,125,105 shares. Over the past year the S&P 500 is down -14.14% while MRNA has risen 5.05%. MRNA lost -$1.55 per share the over the last 12 months.

To see the top 5 stocks in Biotechnology click here.

Go here to read the rest:
Is Moderna Inc (MRNA) Stock Near the Top or Bottom of the Biotechnology Industry? - InvestorsObserver

Biotechnology is not only an exciting career that covers a broad range of career fields engaged in advancing medical technologyits also a quickly growing job choice. In fact, according to Grand View Research, the biotechnology market is expected to reach $727.1 billion by 2025.

The skills and experience that students can gain from biotechnology graduate programs are crucial to excelling in this rapidly evolving field. But not all biotechnology graduate programs are created the samewhile its essential to master the curriculum, some lessons are better grasped through hands-on experience and training.

This is what sets Azusa Pacific Universitys M.S. in Biotechnology apart. The program focuses on internships and masters projects with pharmaceutical, biopharmaceutical, and medical device companies.

Academic laboratories are crucial and, at APU, courses are taught by industry professionals. But with the biotech industry changing continually, it can be a challenge for students to experience current technical advances unless theyre directly in the field. APUs program incorporates onsite internship experiences to ensure every program graduate is well-versed in the industry landscape.

Almost half of the top biotech companies are headquartered in California, in cities likes San Francisco and Los Angeles. APU is just 26 miles from L.A., which gives biotech students many opportunities to work alongside top professionals in the field. Students collaborate with companies like Gilead Sciences, Amgen, and Medtronic, where theyre able to observe state-of-the-art technical practices currently used in the industry. David Dyer, Ph.D., executive director of APUs M.S. in Biotechnology program, explained that this experience also allows students to understand aspects of a companys work environment, including communication, team function, leadership, and management style.

The goal is for grad students to obtain the skills needed to go from classroom to career field seamlessly.

A second reason the M.S. in Biotechnology program emphasizes in-person work with companies is that the company can get a long look at the student as a potential future hire, said Dyer. Companies can also place students on projects where they may require additional assistance.

Justin Hoang, a current biotech student, said that his internship with Grifols was a valuable learning experience. I learned how to operate new systems and software that pertained to the career I wish to pursue after graduation, he noted.

Graduates of APUs biotech program receive a head start on their rsums as well, as theyre able to list their experience with widely recognizable companies. The program prepares individuals for a variety of biotech careers, including those in epidemiology, genetic counseling, and microbiology.

APU alum Najeh Salamah enrolled in the M.S. in Biotechnology program after being away from school for a while. Salamah said, The well-rounded program sets you up for success, and you dont have to be a traditional biology/chemistry major.

Students of the program are required to complete 900 hours of onsite training, so every graduate will be adequately exposed to corporate practice and culturebut you wont be alone throughout the program. Salamah said that the programs faculty, counselors, and director are like family and work to guide their classes to have fruitful and compelling interaction. The faculty want their students to succeed and work to make everyone feel welcome.

Are you interested in becoming part of the biotech family at Azusa Pacific University and working toward your M.S. in Biotechnology? Learn more about the programs associated coursework and academic requirements.

Posted: March 10, 2020

See the article here:
The Benefit of Hands-On Experience in Biotechnology Graduate Programs - Azusa Pacific University

Dublin, March 10, 2020 (GLOBE NEWSWIRE) -- The "Animal Biotechnology - Technologies, Markets and Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering.

Share of biotechnology-based products and services in 2018 is analyzed and the market is projected to 2028. The text is supplemented with 36 tables and 6 figures. Selected 260 references from the literature are appended.

Approximately 124 companies have been identified to be involved in animal biotechnology and are profiled in the report. These are a mix of animal healthcare companies and biotechnology companies. Top companies in this area are identified and ranked. Information is given about the research activities of 11 veterinary and livestock research institutes. Important 110 collaborations in this area are shown.

The report contains information on the following:

This report describes and evaluates animal biotechnology and its application in veterinary medicine and pharmaceuticals as well as improvement in food production. Knowledge of animal genetics is important in the application of biotechnology to manage genetic disorders and improve animal breeding. Genomics, proteomics and bioinformatics are also being applied to animal biotechnology.

Transgenic technologies are used for improving milk production and the meat in farm animals as well as for creating models of human diseases. Transgenic animals are used for the production of proteins for human medical use. Biotechnology is applied to facilitate xenotransplantation from animals to humans. Genetic engineering is done in farm animals and nuclear transfer technology has become an important and preferred method for cloning animals. There is a discussion of in vitro meat production by culture.

Biotechnology has potential applications in the management of several animal diseases such as foot-and-mouth disease, classical swine fever, avian flu and bovine spongiform encephalopathy. The most important biotechnology-based products consist of vaccines, particularly genetically engineered or DNA vaccines. Gene therapy for diseases of pet animals is a fast developing area because many of the technologies used in clinical trials humans were developed in animals and many of the diseases of cats and dogs are similar to those in humans.RNA interference technology is now being applied for research in veterinary medicine

Molecular diagnosis is assuming an important place in veterinary practice. Polymerase chain reaction and its modifications are considered to be important. Fluorescent in situ hybridization and enzyme-linked immunosorbent assays are also widely used. Newer biochip-based technologies and biosensors are also finding their way in veterinary diagnostics.

Biotechnology products are approved by the Center for Veterinary Medicine of the FDA. Regulatory issues relevant to animal biotechnology are described.

List of Topics Covered

Executive Summary1. Introduction to Animal Biotechnology2. Application of Biotechnology in Animals3. A Biotechnology Perspective of Animals Diseases4. Molecular Diagnostics in Animals5. Biotechnology-based Veterinary Medicine6. Research in Animal Biotechnology7. Animal Biotechnology Markets8. Regulatory Issues9. Companies Involved in Animal Biotechnology10. References

For more information about this report visit https://www.researchandmarkets.com/r/qbm3p5

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.comLaura Wood, Senior Press Managerpress@researchandmarkets.comFor E.S.T Office Hours Call 1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT Office Hours Call +353-1-416-8900

Go here to read the rest:
Global Animal Biotechnology Industry Insights, 2018-2028 Featuring Profiles of ~124 Players and 110 Collaborations - Yahoo Finance

SAN FRANCISCO, March 12, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc.(Nasdaq: VIR) today announced that it has signed a letter of intent with Biogen Inc. (Nasdaq: BIIB) for the development and clinical manufacturing of human monoclonal antibodies for the potential treatment of COVID-19, the disease caused by the SARS-CoV-2 virus. Because of the urgency of the situation, the companies have begun work while a Clinical Development and Manufacturing Agreement is being negotiated. Subject to the completion of a definitive agreement, Biogen would continue cell line development, process development, and clinical manufacturing activities in order to advance the development of Virs proprietary antibodies.

These exceptional circumstances presented by the threat of COVID-19 require that we work with great urgency in the interest of the public good, said George Scangos, Ph.D., CEO, Vir. Biogen is one of the global leaders in cell line and process development for advanced biologics; tapping into their capabilities will provide us with a U.S. base for supply and manufacture of antibody therapies.

Vir has identified a number of monoclonal antibodies that bind to SARS-CoV-2, which were isolated from individuals who had survived a SARS (Severe Acute Respiratory Syndrome) infection. The company is conducting research to determine if its antibodies, or additional antibodies that it may be able to identify, can be effective as treatment and/or prophylaxis against SARS-CoV-2.

About Virs Antibody Platform

Vir has a robust method for capitalizing on unusually successful immune responses naturally occurring in people who are protected from, or have recovered from, infectious diseases. The platform is used to identify rare antibodies from survivors that have the potential to treat and prevent rapidly evolving and/or previously untreatable pathogens via direct pathogen neutralization and immune system stimulation. Vir engineers the fully human antibodies that it discovers to enhance their therapeutic potential. This platform has been used to identify and develop antibodies for pathogens including Ebola (mAb114, currently in use in theDemocratic Republic of Congo), hepatitis B virus, influenza A, malaria, and others.

AboutVir Biotechnology

Vir Biotechnology is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of five product candidates targeting hepatitis B virus, influenza A, human immunodeficiency virus, and tuberculosis. For more information, please visit http://www.vir.bio.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as may, will, expect, plan, anticipate, estimate, intend, potential and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Virs expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include statements regarding the companys efforts to neutralize the SARS-CoV-2 virus and identify additional potential therapies for SARS-CoV-2, its ability to address the emerging public health epidemic, and its ability to enter into an agreement with Biogen, and its ability to secure a U.S. base for supply and manufacture of antibody therapies. Many factors may cause differences between current expectations and actual results including unexpected safety or efficacy data observed during preclinical or clinical studies, challenges in neutralizing SARS-CoV-2, difficulty in reaching a definitive agreement with Biogen, challenges of collaborating with other companies or government agencies, and challenges in accessing manufacturing capacity. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Virs filings with theU.S. Securities and Exchange Commission, including the section titled Risk Factors contained therein. Except as required by law, Vir assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

Contact:Vir Biotechnology, Inc.Investors Neera Ravindran, MDHead of Investor Relations & Strategic Communications nravindran@vir.bio+1-415-506-5256

Media Lindy Devereux Scient PR lindy@scientpr.com +1-646-515-5730

Original post:
Vir Biotechnology Announces Intent to Collaborate with Biogen on Manufacturing of Antibodies to Potentially Treat COVID-19 - GlobeNewswire

New data prove that propionic acid modulates the intestine-mediated immune regulation in people with multiple sclerosis (MS).

In Cell the team headed by Aiden Haghikia from University Bochum demonstrated that the administration of propionic acid (PA) in addition to MS standard therapy reduced the relapse rate and the risk of disability increase in the long term. Furthermore, MRI studies indicate that propionic acid may reduce brain shrinkage of patients with Multiple sclerosis (MS), which is regarded as a measure for neuronal cell death.

Haghikia et al. demonstrated that

PA is reduced in MS patients, particularly early after disease manifestation; PA reduction is associated with an altered gut microbiome composition; after 14days of PA supplementation, Treg cell/TH17 imbalance was restored; longitudinal PA supplementation might have clinical implications.

The reseach team together with co-working groups at MDC Berlin and University of Halle-Wittenberg demonstrated that the microbiome composition is altered in MS patients. In addition, for the first time they were able to show a deficiency of propionic acid in the stool and serum of MS patients, which was most pronounced in the earliest phase of the disease. Propionic acid is an EFSA-approved antibacterial food supplement.

"Intestinal bacteria can directly and indirectly influence anatomically distant structures such as the brain," explained study head Haghikia, who together with Flexopharm Brain GMBH & Co. KG holds a patent on the invention. The company markets a related food supplement. "The intestinal microbiome thus corresponds to an independent endocrine organ that is in contact with the environment."

In the current study, the scientists transfered results previously obtained in cell culture and disease models co-developed witha group from Bar-Ilan University in Israel to MS patients: short-chain fatty acids such as propionic acid or its salt propionate led to the increased formation and increased function of T regulatory cells (Tregs) of the immune system. "These cells stop excessive inflammatory reactions and reduce auto-immune cells in the context of autoimmune diseases such as MS," said co-author Ralf Gold, Director of Neurology at St. Josef Hospital. The increase in Treg function is due to improved energy utilization through an altered function of the mitochondria.

However, the short-chain fatty acids represent only a fraction of the metabolic products of intestinal bacteria. "Further research into this largely unknown organ and the knowledge gained from it will make it possible to develop further innovative dietary measures to complement the known therapeutics in the future," commented Haghikia.

See original here:
Nutrition influences the course of MS - European Biotechnology

Here's a roundup of top developments in the biotech space over the last 24 hours:

(Biotech stocks that hit 52-week highsMarch 9.)

(Biotech stocks that hit 52-week lows March 9.)

See also:Attention Biotech Investors: Mark Your Calendar For These March PDUFA Dates

Mesoblast limited (NASDAQ: MESO) said it plans to evaluate its allogenic mesenchymal stem cell product candidate remestemcel-L in patients with acute respiratory distress syndrome caused by COVID-19 in the U.S., Australia, China and Europe.

The company said it is in active discussions with various government and regulatory authorities, medical institutions and pharma companies.

In premarket trading Tuesday, the shares were surging 28.35% to $7.90.

Emergent Biosolutions Inc (NYSE: EBS) said it has entered into an agreement with Novavax, Inc. (NASDAQ: NVAX), under which the former will use its molecule-to-market contract development and manufacturing service to support bringing intothe latter's vaccine candidate to protect against COVID-19 into the clinic.

Emergent will produce the COVID-19 experimental vaccine candidate developed using Novavax's proprietary recombinant protein nanoparticle technology platform. Emergent said it has initiated work and anticipatescommencement of a Phase 1 study within the next four months.

Separately, Novavax said the Coalition for Epidemic Preparedness awarded it an initial funding of $4 million to support its COVID-19 vaccine program.

In premarket trading Tuesday, Emergent shares were adding 0.95% to $53.02 and Novavax shares were surging up 24.35% to $12.46.

GENMAB A/S/S ADR (NASDAQ: GMAB) announced the appointment of Anthony Mancini as EVP and COOeffective March 23. Mancini's rolecalls for himto oversee the company's commercial, corporate development, business development and information technology functions.

Ophthalmic medtech and pharma company Glaukos is set to join the S&P SmallCap 600 Index, effective prior to the open of trading March 13, replacing AK Steel Holding Corporation (NYSE: AKS), which has agreed to be acquired by Cleveland-Cliffs Inc (NYSE: CLF).

Glaukos shares were trading 7.5% higher at $38.49 in the premarket session.

MediciNova, Inc. (NASDAQ: MNOV) said it plans to initiate the development of MN-166 for severe pneumonia and acute respiratory distress syndrome following positive results in a recent preclinical study in an animal model. The animal study showed treatment with the investigational candidate reversed histological changes, including inflammation, hemorrhage, alveolar congestion and alveolar edema.

Medical Resources Acquisition said on Feb. 25 it offered Rockwell Medical Inc (NASDAQ: RMTI) $15 million in equity investment for three board seatscurrently held by John Cooper, Mark Ravich and Lisa Colleran.

The investment firm said Rockwell's board hasfailed to provide appropriate governance, resulting in reckless spending, acash deficiency and a lack of operational controls that have impacted stock performance.

Rockwell acknowledged receiving an email from Medical Resources Acquisition in a press release.

"The Board of Directors is in the process of reviewing the materials submitted by MRAG. Stockholders do not need to take any action at this time," the company said.

The stock was trading 9.37% higher at $3.50 in Tuesday's premarket session.

Acceleron Pharma Inc (NASDAQ: XLRN) saidtreatment with ACE-083 in patients with Charcot-Marie-Tooth disease did not demonstrate functional improvement in aPhase 2 trial.

The companysaid it is discontinuing the development of ACE-083.

Organogenesis Holdings Inc's (NASDAQ: ORGO) fourth-quarter revenues climbed 17% to $74.6 million. The net loss per share narrowed from 12 cents to 4 cents. For 2020, the company guided to revenues of $273 million to $277 million. The results as well as the guidance were above consensus.

The stock jumped 14.56% to $3.54 in after-hours trading.

Aduro BioTech Inc (NASDAQ: ADRO) said its fourth-quarter revenues increased from $2.8 million in 2018 to $3.6 million in 2019. The loss per share narrowed from 33 cents to 24 cents, while analysts expected a narrower loss of 21 cents per share.

The stock slipped 4.89% to $2.92 in after-hours trading.

Assertio Therapeutics Inc (NASDAQ: ASRT) reported fourth-quarter revenues of $59.23 million and a loss of $2.65 per share. In the year-ago quarter, the company reported revenues of $42.6million and a loss of 38 cents per share. On a non-GAAP basis, the company reported a loss of 14 cents per share for the recent quarter compared to expectations for a profit of 14 cents per share.

The stock fell 11.21% to 95 cents in after-hours trading.

The FDA is set to rule on Bristol-Myers Squibb Co's (NYSE: BMY) sBLA for Opdivo + Yervoy as treatment option for patients with advanced hepatocellular carcinoma who werepreviously treated with Bayer AG (OTC: BAYRY) and Onyx Pharma's Nexavar.

Related Link: The Week Ahead In Biotech (March 8-14): Bristol-Myers Awaits FDA Nod For Liver Cancer Combo Therapy, Earnings Flow Continues

2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

See the original post:
The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap...

Biotech stocks rebounded in the week ended March 6, recovering from the previous week's steep sell-off.

The week was light on news flow, barring some smid-cap earnings andCOVID-19 treatment and vaccine news.

The following arekey catalysts in the unfolding week that a biotech investor should stay tuned to.

Barclays Global Healthcare Conference: March 10-12 in Miami, Florida.American Academy of Allergy Asthma and Immunology, or AAAAI, Annual Meeting: March 13-16 in Philadelphia, Pennsylvania.

The FDA is set to rule on Bristol-Myers Squibb Co's (NYSE: BMY) sBLA for Opdivo + Yervoy as a treatment option for patients with advanced hepatocellular carcinoma who were previously treated with Bayer AG (OTC: BAYRY) and Onyx Pharma's Nexavar. The PDUFA date has been set for Tuesday.

Blueprint Medicines Corp (NASDAQ: BPMC) is scheduled to present at the AAAAI annual meeting with Phase 2 data for Avapritinib, which is being evaluated for treating indolent and smoldering systemic mastocytosis.

See also: Attention Biotech Investors: Mark Your Calendar For These March PDUFA Dates

Monday

Tuesday

Wednesday

Friday

Imara, a biopharma company that is developing therapies for rare hemoglobinopathies, has filed to offer 4.45 million shares in an IPO, to be priced between $16 and $18. The company seeks to list its shares on the Nasdaq under the ticker symbol "IMRA."

Revolution Medicines Inc (NASDAQ: RVMD)

Related Link: How The COVID-19 Outbreak Is Benefiting Biotech Investors

2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original post:
The Week Ahead In Biotech (March 8-14): Bristol-Myers Awaits FDA Nod For Liver Cancer Combo Therapy, Earnings Flow Continues - Benzinga